Hims & Hers Health, Inc. Class Action Lawsuit Update: Deadline to File Lead Plaintiff Motion on August 25, 2025

Strategic Insights -

Investors who purchased Hims & Hers Health, Inc. securities between April 29, 2025, and June 23, 2025, are reminded of the August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on their behalf. The lawsuit alleges that the company made false and/or misleading statements about its business, operations, and prospects. Specifically, it is claimed that Hims & Hers promoted and sold illegitimate, knockoff versions of Wegovy, a medication manufactured by Novo Nordisk, which put patient safety at risk. As a result, the company's share price fell significantly on June 23, 2025.

Key Takeaways:

  • The class action lawsuit alleges that Hims & Hers made false and/or misleading statements about its business, operations, and prospects.
  • The lawsuit claims that the company promoted and sold illegitimate, knockoff versions of Wegovy, which put patient safety at risk.
  • As a result of the alleged wrongdoing, the company's share price fell significantly on June 23, 2025.
  • Investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025, are reminded of the August 25, 2025 deadline to file a lead plaintiff motion in the class action.
  • The lawsuit was filed on behalf of investors who purchased or otherwise acquired Hims securities during the Class Period.

Statistics:

  • The company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume.
  • The Class Period is defined as April 29, 2025, and June 23, 2025.

Sources:

  • GlobeNewswire
  • Glancy Prongay & Murray LLP